All In MedTech

Device Trial Radar · NCT05857943

Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Funduscopic Images

Prospective Clinical Trial to Demonstrate the Efficacy and Safety if AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Funduscopic Images Obtained With a Funduscopic Device

Last checked: Nov 20, 2026Latest source record: Nov 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

363

Actual

Start

Mar 29, 2023

Primary completion

Sep 11, 2023

Study completion Oct 10, 2023

Sponsor

Lead sponsor
AEYE Health IncNot on our public-company list
Sponsor type
Industry
First posted
May 15, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AEYE-DS is a software device developed to increase compliance with diabetic retinopathy screening by automatically detecting more-than-mild diabetic retinopathy from digital funduscopic images using AI-based software. This study has been designed to validate the safety and efficacy of the device at primary care and other point of care sites.

Conditions

  • Diabetes Mellitus
  • Diabetic Retinopathy

Interventions

  • AEYE-DS SoftwareDevice

    Eligible participants will undergo the following procedures: Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis. -Additional photographic and OCT images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis. -All study subjects will have their pupils dilated using dilation drops.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity and SpecificityTime frame: 1 year

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Karas Health Care

    Fayetteville, Arkansas

  • Lake Nona Research

    Orlando, Florida

  • The Jackson Clinic

    Jackson, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.